Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00326
|
|||||
| Drug Name |
Sarcosine
|
|||||
| Synonyms |
(Methylamino)acetic acid; (Methylamino)ethanoic acid; 2-(methylamino)acetic acid; AI3-15410; Acetic acid, (methylamino)-; BRN 1699442; CHEBI:15611; CHEMBL304383; Cocoylsarcosine; EINECS 203-538-6; FSYKKLYZXJSNPZ-UHFFFAOYSA-N; Glycine, N-methyl-; H-Sar-OH; Methylamino-Acetic Acid; Methylaminoacetic acid; Methylglycine; N-Methyl glycine; N-Methylaminoacetic acid; N-methyl-Glycine; N-methylglycine; Polysarcosine; SAR; Sarcosin; Sarcosine, 98%; Sarcosinic acid; Sargosine hydrochloride; UNII-Z711V88R5F; Z711V88R5F
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Schizophrenia [ICD11:6A20] | Phase 2 | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C3H7NO2
|
|||||
| Canonical SMILES |
CNCC(=O)O
|
|||||
| InChI |
InChI=1S/C3H7NO2/c1-4-2-3(5)6/h4H,2H2,1H3,(H,5,6)
|
|||||
| InChIKey |
FSYKKLYZXJSNPZ-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 107-97-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 89.09 | Topological Polar Surface Area | 49.3 | ||
| Heavy Atom Count | 6 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
-2.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
102851555
,103260070
,103928493
,104296726
,104668562
,10503566
,117480502
,123055190
,124799851
,125270146
,125324385
,125337494
,126523128
,126595739
,126604360
,126646789
,126676630
,127319579
,127319580
,14842807
,24439439
,24848035
,24899761
,3135884
,3513
,38327572
,413393
,50045496
,50370559
,5077689
,51075215
,57260822
,57264366
,57304408
,57320726
,589772
,608062
,7888914
,7890376
,7979965
,8143301
,8150965
,85089252
,85164986
,85244545
,87243947
,87350276
,87572403
,88828665
,92297466
|
|||||
| ChEBI ID |
CHEBI:15611
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | GLYT1 | Transporter Info | Sodium- and chloride-dependent glycine transporter 1 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT01503359) Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia | |||||
| 2 | Glycine is taken up through GLYT1 and GLYT2 transporters into mouse spinal cord axon terminals and causes vesicular and carrier-mediated release of its proposed co-transmitter GABA. J Neurochem. 2001 Mar;76(6):1823-32. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.